Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
ILIAS Biologics Signed An MOU with HK inno.N For Joint Research
Details : With the MOU, the two companies plan to collaborate - to discover and develop new drug candidates using exosomes, known as the next game-changer in the drug delivery system.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 27, 2022
Lead Product(s) : ILB-202
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ILIAS Biologics Granted Key Patent for Exosome-based Drug Delivery System in the United States
Details : This latest patent is integral to the Company's EXPLOR® platform technology as well as the Exo-Target® products, as the patent covers not only EXPLOR® technology but also its application for various therapeutic cargo proteins developed by ILIAS for lo...
Product Name : ILB-202
Product Type : Protein
Upfront Cash : Inapplicable
July 07, 2020
Lead Product(s) : ILB-202
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable